Elevating Cardiac Care: The Prognostic Power of Atellica IM High-Sensitivity Troponin I

Cardiovascular disease remains the leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC), claiming a life every 33 seconds and causing a heart attack every 40 seconds. Heart attacks, or acute myocardial infarctions (AMI), remain a burden across the U.S. healthcare continuum for both patients and providers.

To understand the role of high-sensitivity troponin I (hs-cTnI) in aiding AMI diagnosis and assessing cardiac risks in individuals, Medical Laboratory Observer (MLO) interviewed two experts: Dr. Christopher deFilippi, MD, MS, a practicing cardiologist with extensive clinical experience, and Dr. Justin Jones, Ph.D., a field medical partner at Siemens Healthineers, a leader in transforming laboratory insights into actionable patient care.

Together, they discuss the evolving role of high-sensitivity cardiac troponin assays, particularly Atellica IM High-Sensitivity Troponin I (TnIH), in improving diagnostic accuracy and patient outcomes.

Unlock the full expert interview to learn how your lab can help clinicians intervene earlier and improve outcomes.

These claims apply to the Atellica IM TnIH assay US IFU and is intended for US audiences only.